All IL-2 fusion proteins imparted tumor growth delay (Fig. 1h, i); however, treatment with the large-format fusions (Fig. 1h) further slowed tumor growth (p = 0.01 for LAIRx-LAIRx-MSAH464Q-IL2 vs. LAIRx-IL2) and enhanced survival (p = 0.01 for LAIRx-LAIRx-MSAH464Q-IL2 vs. LAIRx-IL2; p = 0.04 for LAIR-LAIRx-MSAH464Q-IL2 vs. LAIR-IL2) compared to their small-format counterparts (Fig. 1i). Here, IL2 is linked to neoplasm.